Bristol Myers Squibb | pharmaphorum

Thursday 2 April 2026

Bristol Myers Squibb

News

BMS goes down the Tubulis route for cancer ADCs

Bristol-Myers Squibb has formed another alliance focusing on antibody-drug conjugates (ADCs) for solid tumours, paying German biotech Tubulis $22.75 million upfront to get

News

Leaked data shows stellar efficacy for J&J’s Carvykti

Leaked data shows stellar efficacy for J&J’s Carvykti

Johnson & Johnson was preparing to divulge the data from its eagerly-awaited CARTITUDE-4 trial of CAR-T therapy Carvykti later this year, but a leak of the data has gi

News

BMS upgrades Evotec neurology alliance, now worth up to $4bn

BMS upgrades Evotec neurology alliance, now worth up to $4bn

Bristol-Myers Squibb has expanded a long-running alliance with Evotec once again, paying another $50 million upfront to deepen their collaboration on drugs to treat neurod

News

Chasing BMS, Takeda trumpets TYK2 data in psoriasis

Chasing BMS, Takeda trumpets TYK2 data in psoriasis

Pharma group is hoping for big things, after splashing out $4bn upfront for the drug last year.

News

Exscientia builds cancer pipeline with two BMS drugs

Exscientia builds cancer pipeline with two BMS drugs

LSD1 and MALT1 inhibitors inherited from BMS alliance will be biotech's next cancer candidates.

News

NICE okays neoadjuvant Opdivo in lung cancer

NICE okays neoadjuvant Opdivo in lung cancer

BMS' checkpoint inhibitor is first to be given a green light for use before surgery in NSCLC.